Unique ID issued by UMIN | UMIN000014449 |
---|---|
Receipt number | R000012765 |
Scientific Title | Evaluation of Treatment Response and Quality of Life of Esomeprazole for Reflux Esophagitis Patients |
Date of disclosure of the study information | 2014/07/07 |
Last modified on | 2022/07/07 12:38:38 |
Evaluation of Treatment Response and Quality of Life of Esomeprazole for
Reflux Esophagitis Patients
Evaluation of Treatment Response and Quality of Life of Esomeprazole for
Reflux Esophagitis Patients
Evaluation of Treatment Response and Quality of Life of Esomeprazole for
Reflux Esophagitis Patients
Evaluation of Treatment Response and Quality of Life of Esomeprazole for
Reflux Esophagitis Patients
Japan |
Reflux Esophagitis
Gastroenterology |
Others
YES
The aim of this study is to evaluate treatment response and quality of life of esomeprazole for
reflux esophagitis patients
Efficacy
Response rate by GerdQ questionnaire 4, 8 weeks after administration of esomeprazole
Influence of CYP2C19 Polymorphism on esomaplazole responsiveness
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
esomeprazole 20mg/day for 8 weeks p.o.
20 | years-old | <= |
Not applicable |
Male and Female
The patient who is diagnosed as a reflux esophagitis and has been treated with PPI (expect for esomaprazole) for 4weeks, but GerdQ questionare shows insufficient therapeutic effect.
1,Patients with a history of hypersensitivity to the study drug.
2,Patients in the administration of atazanavir sulfate or a Rirupibirin hydrochloride.
3,Patients with confirmed gastric ulcer, duodenal ulcer by endoscopy.
4,Patients who have unstable merger liver, kidney, heart disease or serious medical conditions.
5,History of gastrointestinal tract resection or vagotomy.
6,Pregnancy and lactation.
7,Patients treated with esomeprazole 14 days before obtaining informed consent
8,Patient in need of administration of the following agents other than the study drug during the study period
(Excluding test drug), histamine H2-receptor antagonist, prokinetics, gastric mucosal protection, anticholinergic drugs, antacids, antidepressants, anti-anxiety drugs, steroids, bisphosphonates.
9,Patients who judged unsuitable for research participation.
80
1st name | Hidemi |
Middle name | |
Last name | Goto |
Nagoya University Graduate School of Medicine
Department of Gastroenterology and Hepatology
466-8560
65 Tsurumai-cho,Showa-ku, Nagoya
052-744-2172
hgoto@med.nagoya-u.ac.jp
1st name | Kohei |
Middle name | |
Last name | Funasaka |
Nagoya University Graduate School of Medicine
Department of Gastroenterology and Hepatology
466-8560
65 Tsurumai-cho,Showa-ku, Nagoya
052-744-2172
k-funa@med.nagoya-u.ac.jp
Nagoya University Graduate School of Medicine, Department of Gastroentelorogy and Hepatology
None
Other
Nagoya University school of medicine
65 Tsurumai-cho,Showa-ku, Nagoya
052-744-2423
ethics@med.nagoya-u.ac.jp
NO
2014 | Year | 07 | Month | 07 | Day |
None
Unpublished
None
3
Because of the difficulty for gathering a new registration, we unfortunately decided to discontinue this study.
2022 | Year | 07 | Month | 07 | Day |
None
None
None
None
Terminated
2013 | Year | 09 | Month | 26 | Day |
2013 | Year | 09 | Month | 01 | Day |
2013 | Year | 09 | Month | 27 | Day |
2017 | Year | 06 | Month | 30 | Day |
2018 | Year | 03 | Month | 31 | Day |
2018 | Year | 04 | Month | 30 | Day |
2018 | Year | 06 | Month | 30 | Day |
2014 | Year | 07 | Month | 01 | Day |
2022 | Year | 07 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012765